These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
402 related articles for article (PubMed ID: 25971300)
1. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. Yan J; Kong LY; Hu J; Gabrusiewicz K; Dibra D; Xia X; Heimberger AB; Li S J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971300 [TBL] [Abstract][Full Text] [Related]
2. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. Latha K; Yan J; Yang Y; Gressot LV; Kong LY; Manyam G; Ezhilarasan R; Wang Q; Sulman EP; Eric Davis R; Huang S; Fuller GN; Rao A; Heimberger AB; Li S; Rao G J Natl Cancer Inst; 2019 Mar; 111(3):292-300. PubMed ID: 29947810 [TBL] [Abstract][Full Text] [Related]
3. Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples. Song Z; Wang Y; Du Y; Zhang Z; Yuan Y Int Immunopharmacol; 2020 Nov; 88():106894. PubMed ID: 32858440 [TBL] [Abstract][Full Text] [Related]
4. FGL2 promotes tumor progression in the CNS by suppressing CD103 Yan J; Zhao Q; Gabrusiewicz K; Kong LY; Xia X; Wang J; Ott M; Xu J; Davis RE; Huo L; Rao G; Sun SC; Watowich SS; Heimberger AB; Li S Nat Commun; 2019 Jan; 10(1):448. PubMed ID: 30683885 [TBL] [Abstract][Full Text] [Related]
5. Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. Xu S; Wei J; Wang F; Kong LY; Ling XY; Nduom E; Gabrusiewicz K; Doucette T; Yang Y; Yaghi NK; Fajt V; Levine JM; Qiao W; Li XG; Lang FF; Rao G; Fuller GN; Calin GA; Heimberger AB J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 24974128 [TBL] [Abstract][Full Text] [Related]
6. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas. Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077 [TBL] [Abstract][Full Text] [Related]
7. Fibrinogen-like protein 2 promotes tumor immune suppression by regulating cholesterol metabolism in myeloid-derived suppressor cells. Wu L; Liu X; Lei J; Zhang N; Zhao H; Zhang J; Deng H; Li Y J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056898 [TBL] [Abstract][Full Text] [Related]
8. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429 [TBL] [Abstract][Full Text] [Related]
9. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389 [TBL] [Abstract][Full Text] [Related]
10. Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma. Richard SA Dis Markers; 2020; 2020():8844313. PubMed ID: 33204365 [TBL] [Abstract][Full Text] [Related]
11. The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. Shalev I; Wong KM; Foerster K; Zhu Y; Chan C; Maknojia A; Zhang J; Ma XZ; Yang XC; Gao JF; Liu H; Selzner N; Clark DA; Adeyi O; Phillips MJ; Gorczynski RR; Grant D; McGilvray I; Levy G Hepatology; 2009 Feb; 49(2):387-97. PubMed ID: 19085958 [TBL] [Abstract][Full Text] [Related]
12. Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy. Sun T; Liu B; Cai L; Zhou Y; Yang W; Li Y J Neurooncol; 2024 Jul; 168(3):457-471. PubMed ID: 38652401 [TBL] [Abstract][Full Text] [Related]
13. Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma. Kesarwani P; Prabhu A; Kant S; Chinnaiyan P Cancer Immunol Immunother; 2019 Jul; 68(7):1107-1120. PubMed ID: 31119318 [TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419 [TBL] [Abstract][Full Text] [Related]
16. Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells. Authier A; Farrand KJ; Broadley KW; Ancelet LR; Hunn MK; Stone S; McConnell MJ; Hermans IF Int J Cancer; 2015 Jun; 136(11):2566-78. PubMed ID: 25363661 [TBL] [Abstract][Full Text] [Related]
17. Stroma-derived Fibrinogen-like Protein 2 Activates Cancer-associated Fibroblasts to Promote Tumor Growth in Lung Cancer. Zhu Y; Zhang L; Zha H; Yang F; Hu C; Chen L; Guo B; Zhu B Int J Biol Sci; 2017; 13(6):804-814. PubMed ID: 28656005 [TBL] [Abstract][Full Text] [Related]
18. Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells. Mukherjee S; Fried A; Hussaini R; White R; Baidoo J; Yalamanchi S; Banerjee P J Exp Clin Cancer Res; 2018 Jul; 37(1):168. PubMed ID: 30041669 [TBL] [Abstract][Full Text] [Related]
19. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Hu J; Yan J; Rao G; Latha K; Overwijk WW; Heimberger AB; Li S Int Rev Immunol; 2016 Jul; 35(4):325-339. PubMed ID: 25259408 [TBL] [Abstract][Full Text] [Related]
20. Deletion of Fibrinogen-like Protein 2 (FGL-2), a Novel CD4+ CD25+ Treg Effector Molecule, Leads to Improved Control of Echinococcus multilocularis Infection in Mice. Wang J; Vuitton DA; Müller N; Hemphill A; Spiliotis M; Blagosklonov O; Grandgirard D; Leib SL; Shalev I; Levy G; Lu X; Lin R; Wen H; Gottstein B PLoS Negl Trop Dis; 2015 May; 9(5):e0003755. PubMed ID: 25955764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]